



Cellular Senescence in Age-Related Diseases: Pathophysiology and Therapeutic Approaches

Guest Editor:

Dr. David J. Rademacher

Stritch School of Medicine, Core
Microscopy Facility and
Department of Microbiology and
Immunology, Loyola University
Chicago, Chicago, IL USA

Deadline for manuscript
submissions:

31 October 2024

Message from the Guest Editor

As cellular senescence, a central hallmark of aging, plays an important role in age-related diseases including diabetes, cardiovascular disease, cancer, and neurodegenerative diseases, interventions targeting senescence are potential therapies for these diseases. The finding of an increased life span in murine models after the removal of senescent cells underscored the utility of targeting senescence for therapeutic benefits. Several therapeutic approaches have been developed. These include the development of drugs that selectively eliminate senescent cells, known as senolytics, the development of drugs that modulate the SASP, known as senomorphics, and the development of drugs that revert senescence to allow senescent cells to enter the cell cycle, known as senoreverters. This Special Issue welcomes articles that clarify the molecular and physiological properties of senescent cells, shed light on the role of cellular senescence in the pathophysiology of age-related diseases, or describe the development of novel therapeutic approaches targeting cellular senescence.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)